Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
27/05/2026 13:14
BRIEF-Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx May 27 (Reuters) - Mira Pharmaceuticals Inc MIRA.O:
ENTERED INTO AMENDMENT NO 1 TO EXCLUSIVE LICENSE AGREEMENT WITH MIRALOGX LLC - SEC FILING
EXPANDS KETAMIR-2 PATENT PORTFOLIO TO 10 MAJOR MARKETS - SEC FILING
Source text: [ID:n0001493152-26-025335]
Further company coverage: MIRA.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing